{"url_path":"/sec/nspr/8-k/2026-06-11/item-7-01","section_key":"item-7-01","section_title":"Item 7.01 Regulation FD Disclosure.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-11","source_url":"https://www.sec.gov/Archives/edgar/data/1433607/0001493152-26-028221-index.html","accession_number":"0001493152-26-028221","cik":"0001433607","ticker":"NSPR","issuer_name":"InspireMD, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1433607/0001493152-26-028221-index.html","primary_entity_key":"0001433607","primary_entity_name":"InspireMD, Inc."},"word_count":165,"has_tables":true,"body_markdown":"**Item\n7.01. Regulation FD Disclosure.**\n\n \n\nOn\nJune 11, 2026, InspireMD, Inc. (the “Company”) issued a press release titled “InspireMD Announces 30-Day Results from\nthe CGUARDIANS II Clinical Trial of the CGuard Prime 80 cm Implant for Use in TCAR Procedures.” A copy of the press release is\nfurnished herewith as Exhibit 99.1 to this Form 8-K and is incorporated by reference in this Item 7.01.\n\n \n\nIn\naccordance with General Instruction B.2 of Form 8-K, the information in this Form 8-K that is furnished pursuant to this Item 7.01, including\nExhibit 99.1, shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as\namended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be incorporated by reference\ninto any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as\nshall be expressly set forth by specific reference in such filing."}